Use of glucagon-like peptide-1 receptor agonists for type 2 diabetes mellitus and outcomes of inflammatory bowel disease.
Aliment Pharmacol Ther
; 60(5): 620-632, 2024 Sep.
Article
en En
| MEDLINE
| ID: mdl-38938071
ABSTRACT
BACKGROUND:
Glucagon-like peptide-1 receptor agonists (GLP-1RA) show anti-inflammatory properties.AIM:
To evaluate their clinical impact on inflammatory bowel disease (IBD) outcomes.METHODS:
Retrospective cohort study utilising the TriNetX database comparing IBD-specific outcomes in patients with ulcerative colitis (UC) or Crohn's disease (CD) and type 2 diabetes mellitus (T2DM) on GLP-1RA compared to oral hypoglycaemic agents. The primary outcome was hospitalisation requiring intravenous steroids and IBD-related surgery within 3 years. We performed 11 propensity score matching (PSM) for demographics, co-morbid conditions, BMI, laboratory values, HbA1c, and IBD medications including steroids.RESULTS:
We identified 1130 patients in the UC GLP-1RA cohort (mean age 58.9 ± 11.6 years, 56.3% female, 70.2% White, 57.2% with obesity) and 1140 patients in the CD GLP-1RA cohort (mean age 56.7 ± 11.5, 61.9% female, 73.6% White, 56.2% with obesity). After PSM, there was no difference in the risk of intravenous steroid use (aHR 1.21, 95% CI 0.92-1.59) but a lower risk of colectomy (aHR 0.37, 95% CI 0.14-0.97) between the UC GLP-1RA and control cohort. There was no difference in the risk of intravenous steroid use (aHR 1.04, 95% CI 0.80-1.34) but a lower risk of surgery (aHR 0.55, 95% CI 0.36-0.84) between the CD GLP-1RA and CD control cohort. There was no difference in the risk of oral steroid use or advanced therapy initiation in the UC and CD GLP-1RA than control cohorts.CONCLUSIONS:
We found an association between lower risk of IBD-related surgery and GLP-1RA use for T2DM in patients with UC or CD.
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Colitis Ulcerosa
/
Diabetes Mellitus Tipo 2
/
Receptor del Péptido 1 Similar al Glucagón
/
Hipoglucemiantes
Límite:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Aliment Pharmacol Ther
Asunto de la revista:
FARMACOLOGIA
/
GASTROENTEROLOGIA
/
TERAPIA POR MEDICAMENTOS
Año:
2024
Tipo del documento:
Article
País de afiliación:
Estados Unidos